Guardion Health Sciences (Guardion Health Sciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Guardion Health Sciences's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Guardion Health Sciences could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Guardion Health Sciences's Cash-to-Debt or its related term are showing as below:

GHSI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 109.7 Max: No Debt
Current: No Debt

During the past 9 years, Guardion Health Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 109.70.

GHSI's Cash-to-Debt is ranked better than
99.71% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs GHSI: No Debt

Guardion Health Sciences Cash-to-Debt Historical Data

The historical data trend for Guardion Health Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Guardion Health Sciences Cash-to-Debt Chart

Guardion Health Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

18.94

19.58

349.62

2,663.75

No Debt

Guardion Health Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Guardion Health Sciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardion Health Sciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Cash-to-Debt falls into.

Guardion Health Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Guardion Health Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Guardion Health Sciences had no debt ⁽¹⁾.

Guardion Health Sciences's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Guardion Health Sciences had no debt ⁽¹⁾.

Guardion Health Sciences (NAS:GHSI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Guardion Health Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardion Health Sciences (Guardion Health Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0QTA:Germany

Address

2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098

Website

https://www.guardionhealth.com

Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.

Executives

Katharine Joan Cox	officer: Chief Accounting Officer	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall	officer: CEO & President	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff	10 percent owner	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff	other: See Footnote 1	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs	director	2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes	director, officer: Chief Executive Officer	2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano	director	131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin	officer: Chief Accounting Officer	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan	officer: Chief Commercial Officer	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt	officer: Chief Financial Officer	1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson	director	C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans	director, officer: Chief Scientific Officer	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans	10 percent owner	4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth	officer: General Counsel and Secretary	15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten	director	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367